Alkermes plc. Deferred Tax Assets, Operating Loss Carryforwards
Alkermes plc. (ALKS) had Deferred Tax Assets, Operating Loss Carryforwards of $238.13 million as of 2022-12-31, per its 10-K filed 2023-02-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2023-02-16
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $238.13M.
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards $222.51M.
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards $233.75M.
- 2019-12-31: Deferred Tax Assets, Operating Loss Carryforwards $227.87M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2022-12-31 | $238.13M 10-K · filed 2023-02-16 |
| 2021-12-31 | $222.51M 10-K · filed 2023-02-16 |
| 2020-12-31 | $233.75M 10-K · filed 2022-02-16 |
| 2019-12-31 | $227.87M 10-K · filed 2021-02-11 |
| 2018-12-31 | $198.63M 10-K · filed 2020-02-13 |
| 2017-12-31 | $177.44M 10-K · filed 2019-02-15 |
| 2016-12-31 | $156.15M 10-K · filed 2018-02-16 |
| 2015-12-31 | $128.63M 10-K · filed 2017-02-17 |
| 2014-12-31 | $83.28M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |